News | February 23, 2022
Complement Therapeutics raises €5 million seed financing
Appoints Dr Rafiq Hasan as CEO
Appoints Dr Rafiq Hasan as CEO
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
He has over 22 years of experience in pharmaceutical sales & business development
It is a novel oral NLRP3 inflammasome inhibitor
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Subscribe To Our Newsletter & Stay Updated
